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Møller S, Iversen JS, Krag A, Bie P, Kjær A, Bendtsen F.
Reduced baroreflex sensitivity and pulmonary dysfunction in alco-
holic cirrhosis: effect of hyperoxia. Am J Physiol Gastrointest Liver
Physiol 299: G784–G790, 2010. First published July 8, 2010;
doi:10.1152/ajpgi.00078.2010.—Patients with cirrhosis exhibit im-
paired regulation of the arterial blood pressure, reduced baroreflex
sensitivity (BRS), and prolonged QT interval. In addition, a consid-
erable number of patients have a pulmonary dysfunction with hypoxe-
mia, impaired lung diffusing capacity (DLCO), and presence of hepa-
topulmonary syndrome (HPS). BRS is reduced at exposure to chronic
hypoxia such as during sojourn in high altitudes. In this study, we
assessed the relation of BRS to pulmonary dysfunction and cardio-
vascular characteristics and the effects of hyperoxia. Forty-three
patients with cirrhosis and 12 healthy matched controls underwent
hemodynamic and pulmonary investigations. BRS was assessed by
cross-spectral analysis of variabilities between blood pressure and
heart rate time series. A 100% oxygen test was performed with the
assessment of arterial oxygen tensions (PaO2) and alveolar-arterial
oxygen gradient. Baseline BRS was significantly reduced in the
cirrhotic patients compared with the controls (4.7 0.8 vs. 10.3 2.0
ms/mmHg; P  0.001). The frequency-corrected QT interval was
significantly prolonged in the cirrhotic patients (P  0.05). There was
no significant difference in BRS according to presence of HPS, PaO2,
DLCO, or Child-Turcotte score, but BRS correlated with metabolic and
hemodynamic characteristics. After 100% oxygen inhalation, BRS
and the QT interval remained unchanged in the cirrhotic patients. In
conclusion, BRS is significantly reduced in patients with cirrhosis
compared with controls, but it is unrelated to the degree of pulmonary
dysfunction and portal hypertension. Acute hyperoxia does not sig-
nificantly revert the low BRS or the prolonged QT interval in cirrho-
sis.
portal hypertension; lung function; cardiovascular regulation; hyper-
oxia; bioactive substances
PATIENTS WITH CIRRHOSIS AND portal hypertension often develop
cardiopulmonary complications that may affect the course of
the disease (17, 29, 41). Many of these complications can be
attributed to a splanchnic and systemic vasodilatation that leads
to a hyperdynamic circulation with increased cardiac output
(CO) and heart rate (HR) and reduced arterial blood pressure
and systemic vascular resistance (SVR) (29, 45). The resulting
central hypovolemia activates a number of vasoconstrictive
systems such as the sympathetic nervous system (SNS), the
renin-angiotensin-aldosterone system (RAAS), vasopressin,
and endothelin-1 (ET-1) (4, 28). This neurohumoral imbalance
is a basic part of an autonomic dysfunction that affects cardio-
vascular regulation in cirrhosis (6, 9). Thus patients with
advanced cirrhosis have cardiac dysfunction with prolonged
QT interval and abnormal blood pressure regulation partly
owing to reduced baroreflex sensitivity (BRS) (13, 16, 29, 32,
36, 51). In addition, a considerable number of the patients
exhibit pulmonary dysfunction with hypoxemia and impaired
lung diffusing capacity (DLCO), and some patients develop a
hepatopulmonary syndrome (HPS) (8, 31, 33, 42).
In healthy individuals, BRS is reduced at exposure to acute
and chronic hypoxia such as during sojourn in or simulation of
high altitudes (11, 40, 43, 44). Moreover, BRS is reduced in
patients with chronic obstructive pulmonary disease partly
because of central effects of hypoxia (38). Therefore, the
present study was undertaken 1) to assess the relation between
the reduced BRS and pulmonary dysfunction and 2) to study
the effects of hyperoxia on BRS, QT interval, and neurohu-
moral regulatory systems in patients with cirrhosis and in
healthy controls. We hypothesized that oxygen inhalation
could fully or partly revert BRS and the neurohumoral changes
in cirrhosis.
METHODS
Study Population
Forty-three patients aged 57.4 9.1 (mean SD) yr (14 women and
29 men) were entered in the study. All patients had verified alcoholic
cirrhosis, i.e., an alcohol consumption exceeding 50 g alcohol per day for
more than 5 yr. All patients had abstained from alcohol for at least 2 mo
before the study. Cirrhosis was diagnosed on liver biopsy in 30% or
classical, accepted clinical and biochemical criteria and presence of
portal hypertension. Patients were stratified according to the modified
Child-Turcotte score, and additionally the MELD score (The Model
for End-Stage Liver Disease) was calculated. Twenty-four patients
had ascites confirmed by ultrasonography. Diuretics were stopped 24
h before the study. None of the patients were taking cardiovascular
medication, neither beta-blockers nor calcium channel blockers. None
of the patients had signs of infections or received antibiotics within 3
wk before the study or during the study period. An age-matched
control group consisted of 12 volunteers (6 women and 6 men) aged
53.9  4.8 yr without liver disease. None were taking medication.
Twenty-four of the patients and seven controls were smokers. The
patients and controls were instructed not to smoke 6 h prior to the
investigations.
Patients and controls participated after giving their informed and
signed consent, in accordance with the Helsinki II Declaration, and
the study was approved by the local Ethics Committee for Medical
Research in Copenhagen (journal no. KF 11-057/03). No complica-
tions or side effects were encountered during the study. Clinical,
biochemical, and hemodynamic characteristics of the patient and
control groups are shown in Table 1.
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Study Protocol
In the morning, all patients underwent hemodynamic investigations
including determination of BRS and pulmonary investigations includ-
ing DLCO and contrast-enhanced echocardiography (CEE).
Hemodynamic investigations. Hepatic veins, right atrium, and
femoral artery were catheterized as described elsewhere (25). The
hepatic venous pressure gradient (HVPG) was determined as the
wedged minus free hepatic vein pressures. The hepatic blood flow,
postsinusoidal resistance, indocyanine green clearance (ICG), and
galactose elimination capacity were determined as previously de-
scribed (25, 31).
CO was measured by the indicator dilution method, as previously
described (25). SVR (expressed in dyn·s·cm5) was assessed as 80 
(MAP  RAP/CO, where MAP is mean arterial pressure and RAP is
right atrial pressure), pressures were expressed in mmHg, and CO in
liters per minute. The central circulation time representing the mean
indicator sojourn in the central blood volume (CBV) and the CBV
itself were both assessed in accordance with the kinetic theory, as
described earlier (25, 30). An indwelling polyethylene catheter was
placed in the femoral artery, and the arterial blood pressures were
measured directly by a capacitance transducer. HR was determined by
ECG monitoring. Stroke volume (SV) was determined as CO/HR.
Pulse pressure (PP) as systolic blood pressure  diastolic blood
pressure and arterial compliance (AC) as PP/SV (15).
Pulmonary investigations. Arterial oxygen tension (PaO2), carbon
dioxide tension (PaCO2), and oxygen saturation were measured by an
ABL-510 (Radiometer, Copenhagen, Denmark). The alveolar-arterial
oxygen gradient [(A-a)PO2] was calculated from the alveolar gas
equation: (A-a)PO2  [FIO2(PB  47)  (PACO2/R)FIO2(1 
R)(PACO2/R)]  PaO2, where FIO2 is the O2 inspiratory fraction; this
was set to 0.21 during breathing room air and to 1.00 during 100%
oxygen inhalation. PB is the barometric pressure, PACO2 is the alveolar
PCO2, assumed to be equal to PaCO2, and R is the respiratory quotient
estimated to 0.80 (31). To diagnose HPS, a CEE was done by agitating
a mixture of 9 ml of saline and 1 ml of blood in two 10-ml syringes
connected through a three-way stopcock producing microbubbles as
previously described (1). To detect microbubbles, we used an apical
four-chamber view with a 3-MHz transducer (Acuson Sequoia 512,
Mountain View, CA). Four patients had a positive CEE (34).
Spirometric data and diffusing capacity (carbon monoxide diffus-
ing capacity, DLCO) was measured by a single-breath technique, as
described elsewhere (24). The DLCO was adjusted for the alveolar
volume (VA) as the diffusing coefficient (DLCO/VA). Static and dy-
namic volumes and diffusing capacity and coefficient were measured
by a Jaeger Body Box System (Erich Jaeger, Würzburg, Germany)
and reported as actual values measured and percent of predicted
reference values.
Measurement of BRS. Information on the source of variability of
blood pressure and the R-R interval can be obtained by spectral
analysis. The total spectrum of frequencies can be divided into three
bands: low (0.02–0.06 Hz), mid (0.07–0.14 Hz), and high range (0.15–
0.40 Hz). The slow variations are related to the vasomotor tone, variations
in the mid frequency band are believed to originate from the character-
istics of the blood pressure control system itself, and the variations in the
high frequency band are mainly attributed to respiratory activity and are
mainly of parasympathetic origin (39). The modulus (gain) function
specifies the ratio between changes in R-R interval time and changes
in systolic blood pressure (ms/mmHg) in the specific frequency band.
Because the modulus in the mid frequency band reflects the function
of the blood pressure controls system, it provides a useful measure of
BRS (39). In this study, the BRS was assessed by cross-spectral
analysis of variabilities between 5-min recordings of intra-arterial
systolic blood pressure values and ECG-derived HR time series. It is,
however, important to emphasize that this method assesses the barore-
flex control of the heart rate and not directly the SNS activity and that
its relation to various frequency bands may not be absolute (21).
Measurement of QT interval. We recorded ECG by a conventional
noncomputerized equipment (Megacart, Siemens-Elema, Erlangen,
Germany). The QT interval was determined on the ECG (50 mm/s) as
described elsewhere (13). In brief, the QT interval length (time of
electric systole) was taken from the onset of the QRS complex to
the end of the T wave (i.e., return to the T-P baseline) and was only
measured with a stable baseline. In the few cases where U waves
were present the QT interval was measured to the nadir of the
curve between the T and the U waves. QT intervals were frequency
corrected (QTC) with the Bazett formula: QTCQT(RR)1/2, where RR
is the R-R interval in seconds, or according to Fridericia’s cube root
formula: QTFQT/RR1/3. Prolonged QTC was defined as QTC 0.440
s1/2. The QT interval was determined blindly, i.e., with no knowledge of
the diagnosis or clinical and hemodynamic variables.
Assays
Norepinephrine. Plasma norepinephrine concentrations were deter-
mined by a commercial available ELISA kit (Labor Diagnostika Nord,
Nordhorn, Germany). Intra-assay and interassay coefficients of vari-
ation were 10 and 15%, respectively, and the detection limit was 0.01
ng/ml.
Renin. The circulating plasma renin concentration was determined
by a commercially available two-site immunoradiometric assay
(IRMA; DGR International) as previously described (26). Samples
were collected in ice-chilled test tubes containing aprotinin-heparin
and EDTA. The detection limit was 0.31 pg/ml, intra- and interassay
variations were 2%, and the median concentration in 536 healthy
subjects was 26 pg/ml (range: 5.2–33.4 pg/ml).
Angiotensin II. Angiotensin II in plasma was determined after
extraction by use of a specific antibody (Ab-5–030682), as described
previously (5). The detection limit was 1.4 pg/ml, and the extraction
recovery of unlabeled angiotensin II added to plasma was 80%. The
Table 1. Clinical, biochemical, and hemodynamic
characteristics of 43 patients with cirrhosis and 12 controls
Patients with
Cirrhosis
(n  43)
Controls
(n  12)
Patient characteristics
Sex, male/female 29/14 6/6
Age, yr 57.4 9.1 53.9  4.8
Ascites,  19/24 (0/12)
Child class, A/B/C 17/18/8 n.a.
Child score 6.7 2.0 n.a.
MELD Score 11.0 2.6 n.a.
Biochemistry
Plasma coagulation factors II,VII, and X,
units; 0.70–1.30 0.62 0.18* 0.97  0.27
Serum albumin, mol/l; 540–800 520  95* 557  50
Serum bilirubin, mol/l; 2–17 16 (4–69)* 7 (3–11)
Serum sodium, mmol/l; 136–146 139 5 141  3
Serum creatinine, mmol/l: 120 84  23 73  13
Hemodynamics
Hepatic venous pressure gradient,
mmHg: 5 15.3  6.3* 1.5  0.7
Hepatic blood flow, l/min, 0.5–2.3 1.29 0.73* 0.95  0.23
Mean arterial blood pressure, mmHg 95.1 15.8 93.1  12.0
Systemic vascular resistance, dyn  s  cm5 1137  387* 1567  475
Arterial compliance, mmHg/ml 1.32 0.39* 1.04  0.10
Heart rate, min1 75  14* 65  9
Cardiac output, l/min 6.8 2.1* 5.6  0.7
Central circulation time, s,14–28 12.1 3.8* 19.4  4.4
Central blood volume, ml/kg 18.4 4.2* 23.4  6.9
Plasma volume, ml/kg 50.9 8.4* 44.5  5.0
Data are given as means  SD (median and total range for serum bilirubin).
MELD, Model for End-Stage Liver Disease; n.a., not applicable. *P 0.05 vs.
controls.
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intra-assay and interassay coefficients of variation were 4 and 10%,
respectively.
Aldosterone. Plasma aldosterone was measured using a commercial
kit (COAT-ACOUNT, Diagnostic Products, Los Angeles, CA). The
detection limit was 11 pg/ml. Recovery was 87%. The intra-assay and
interassay coefficients of variation were 3 and 5%, respectively.
Endothelin-1. We determined plasma endothelin concentrations by
a commercial available ELISA kit (Biomedica Gruppe, Wien Aus-
tria). Intra-assay and interassay coefficients of variation were 4 and
6%, respectively, and the detection limit was 0.01 fmol/ml.
Pro-ANP. Plasma pro-atrial natriuretic peptide (ANP) and brain
natriuretic peptide (BNP) concentrations were determined by a com-
mercial available ELISA kit (Biomedica Gruppe, Wien, Austria).
Intra-assay and interassay coefficients of variation were 2 and 4%,
respectively and the detection limit was 0.034 nmol/ml.
BNP. BNP was measured by an automated two-site sandwich
immunoassay technique using chemiluminescence (ADVIA Centaur,
Siemens, Germany). The assay measures the physiologically active
COOH-terminal peptide (77–108). The sensitivity of the assay was 2
pg/ml, and the intra- and interassay coefficients of variation were 1.2
and 2.3%, respectively (47).
Oxygen inhalation. After measurements of the baseline data, a
sealed oxygen mask was placed over the nose and mouth of the supine
patient and humidified 100% oxygen (15 l/min) was given for 20 min.
At the end of that period, blood pressures, BRS, QT interval, and
vasoactive substances were again measured.
Statistical Analyses
Data are presented as means  SD or medians and interquartile
ranges in case of a nonnormal distribution. Statistical analyses were
performed by unpaired Student’s t-test or the Mann-Whitney test,
ANOVA or ANOVA on ranks, paired Student’s t-test, or Wilcoxon’s
test, as appropriate. Correlation analyses between independent vari-
ables were performed by the Spearman’s rank correlation test. A P
value less than 5% was considered significant.
RESULTS
Patients with cirrhosis had significant portal hypertension,
with a mean hepatic venous pressure gradient of 15.3  6.3
mmHg, augmented hepatic perfusion and impaired liver func-
tion, as evaluated by the Child and MELD scores (Table 1).
The patients also showed signs of vasodilatation with a reduced
SVR and increased arterial compliance and a hyperdynamic
circulation with increased CO and HR (Table 1).
Lung Function
Four patients had a positive CEE, indicative of presence of
HPS. Spirometric data showed normal results except for five
patients who were considered to have a chronic obstructive
lung disease with mild spirometric reduction. DLCO and
DLCO/VA were significantly reduced in 31 and 37 of the
patients, respectively (Table 2). PaO2 was below the lower
normal reference threshold of 10.6 kPa in 13 patients and
(A-a)PO2 was increased above 2.6 kPa in 27 patients (Table 3).
Baroreflex Sensitivity
The baseline BRS was significantly reduced in the cirrhotic
patients compared with the controls (4.7  0.8 vs. 10.3  2.0
ms/mmHg; P  0.001), Fig. 1. There was no significant
difference in BRS according to presence of HPS as evaluated
by CEE, the Child-Turcotte or MELD scores, or the presence
of ascites. There were no significant correlations between
baseline BRS and PaO2, (A-a)PO2, DLCO, or DLCO/VA. After
100% oxygen inhalation, BRS remained unchanged in the
cirrhotic patients and was still significantly lower in the
cirrhotic patients than in the controls (P  0.005). After
oxygen inhalation, arterial blood pressures increased
slightly by 2– 6% in both patients and controls, and HR
decreased in both patients and controls, but the change was
less pronounced in the patients, 3% vs. 10% in the
controls (P  0.02).
At baseline, BRS correlated with serum potassium (r 
0.41, P  0.005), serum bilirubin (r  0.30, P  0.05), HR
(r  0.58, P  0.0001), and AC (r  0.30, P  0.05).
QT Interval
The mean QTC and QTF intervals were significantly pro-
longed in the cirrhotic patients compared with the controls
(P  0.05, Table 4, Fig. 2). After oxygen inhalation, there was
an insignificant trend toward a further prolongation of the QTC
and QTF intervals (Table 4) in cirrhotic patients but not in
controls. According to the median change in the QTC interval
of 4.2 ms, the patients were divided into two groups. In the
low-QTC interval group, median baseline QTC interval was
significantly longer than in the high-QTC change interval (0.46
vs. 0.44 s, P  0.005). The change in BRS was borderline
significantly smaller in the low- than in the high-change QTC
group (0.2 vs. 2.0 ms/mmHg, P  0.08). Baseline BRS
correlated significantly with QT (r  0.61, P  0.0001) and
QTF (r  0.37, P  0.01) intervals.
Vasoactive Substances
The plasma renin concentrations were significantly increased in
patients with cirrhosis compared with controls (P 0.005, Table 5).
After oxygen inhalation, a small but significant decrease in
renin concentration of 10% was seen in the cirrhotic patients
(P  0.001). Plasma renin concentrations fell significantly more
in the cirrhotic patients than in the controls (P  0.02, Table 5).
At baseline plasma renin concentrations correlated with HVPG (r
0.43, P  0.002), systolic blood pressure (0.66, P  0.0001),
plasma angiotensin II concentrations (r  0.79, P  0.0001), and
plasma aldosterone concentrations (r  0.78, P  0.0001).
There was no significant difference between plasma angio-
tensin II concentrations between patients and controls either at
baseline or after oxygen inhalation. At baseline plasma angio-
tensin II concentrations correlated with serum sodium (r 
0.40, P  0.005), Child and MELD scores (r  0.30, P 
Table 2. Spirometry, total lung capacity, and lung diffusing
capacity of 43 patients
Patients with
Cirrhosis (n  43) Predicted Value, %
FVC, liters 3.76 1.05 100 16
FEV1, liters 2.91  0.80 96 16
Tiffeneau index, FEV1/FVC 0.78  0.08
TLC, liters 5.72 1.56 92 18
RV, liters 2.08 0.90 95 41
DlCO, mmol  min1  kPa1 5.92  1.69 66 19
Diffusing coefficient, DLCO/Va,
mmol  min1  kPa1  l1 1.26  0.75 61 13
FVC, forced vital expiratory capacity; FEV1, forced expiratory volume in
first second; TLC, total lung capacity; RV, residual volume; DlCO, carbon
monoxide diffusing capacity; Va, alveolar volume.
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0.05), systolic blood pressure (0.57, P  0.0001), CBV
(ml/kg ideal body weight, r  0.28, P  0.05), QTC (r 
0.34, P  0.02), and plasma aldosterone concentrations (r 
0.68, P  0.0001).
The plasma aldosterone concentrations were significantly
increased in patients with cirrhosis compared with controls
(P 0.05, Table 5). A slight but significant fall was seen in the
aldosterone concentrations in both cirrhotic patients and con-
trols after oxygen inhalation (P  0.01), but there was no
significant difference in the reduction between the groups
(Table 5). At baseline plasma aldosterone concentrations cor-
related with Child score (r  0.41, P  0.005), HVPG (r 
0.30, P  0.03), RAP (r  0.32, 0.02), systolic blood
pressure (0.62, P  0.0001), CO (r  0.54, P  0.0001),
CBV (ml/kg ideal body weight, r0.39, P 0.005), and PP
(0.58, P  0.0001).
The plasma pro-ANP concentrations were significantly in-
creased in patients with cirrhosis compared with controls (P 
0.001, Table 5). A slight but significant increase was seen in
the pro-ANP concentrations in the cirrhotic patients after
oxygen inhalation (P  0.05). At baseline, plasma pro-ANP
concentrations correlated with serum creatinine (r 0.36, P
0.02), serum sodium (r  0.33, P  0.03), serum albumin
(r0.50, P 0.001), HVPG (r 0.30, P 0.05), and ICG
(r  0.37, P  0.02). There were no significant correlations
of pro-ANP to BRS or RAP.
Plasma BNP concentrations were significantly higher in the
cirrhotic patients than in the controls at baseline (P  0.01) as
well as during oxygen inhalation (P  0.005). During oxygen
inhalation BNP increased further in the cirrhotic patients (P 
0.001), whereas it remained unchanged in the controls. The
patients were divided into two groups according to the median
change in BNP of 6.7 pg/ml. In the low-BNP change group, the
median change in BRS was borderline significantly lower than
in the high-BNP change group (2.3 vs. 4.6 ms/mmHg, P 
0.07). At baseline, BNP concentrations correlated to indicators
of liver dysfunction such as the MELD score (r  0.45, P 
0.005) and serum albumin (r  0.62, P  0.0001), splanch-
nic hemodynamics such as ICG (r  0.52, P  0.0001) and
HVPG (r  0.43, P  0.005), and cardiac and circulatory
function such as HR (r  0.40, P  0.01), RAP (r  0.33,
P  0.05), and QT interval (r  0.35, P  0.05). There were
no significant correlations between BNP and pulmonary func-
tion. The change in BNP correlated significantly with baseline
BRS (r  0.33, P  0.05).
Table 3. Blood gases, oxygen saturation, and
alveolar-arterial oxygen gradient in 43 patients with
cirrhosis and in 12 controls
Patients with Cirrhosis
(n  43) Controls (n  12)
Arterial O2 tension, kPa 11.5  1.8 11.0 1.2
Arterial O2 saturation, % 96  2 95  4
Alveolar-arterial O2 gradient, kPa 3.1  1.8 2.2 1.2
Arterial CO2 tension, kPa 4.5  0.6* 5.5 0.4
Arterial pH 7.44  0.05* 7.41 0.01
Positive CEE, yes/no 4/39 0/12
Data are given as means  SD. CEE, contrast-enhanced echocardiography.
*P  0.05 vs. controls.
Fig. 1. Baroreflex sensitivity (BRS) in 43 patients with cirrhosis and controls
at baseline and after 100% oxygen inhalation. *P  0.001 vs. controls.
Table 4. Q-T interval, QTc, and QTF in 43 patients with
cirrhosis and 12 controls at baseline and after
oxygen inhalation
Patients with Cirrhosis (n  43) Controls (n  12)
Q-T interval, s 0.409  0.039 0.401 0.030
Q-T interval, s-O2 0.425  0.044† 0.410 0.025
QTC, s1/2 0.453  0.031* 0.409 0.027
QTC, s1/2-O2 0.466  0.056* 0.405 0.011
QTF, s2/3 0.439  0.027* 0.406 0.024
QTF, s2/3-O2 0.451  0.049* 0.406 0.008
Data are given as means  SD. -O2, after oxygen inhalation; QTC and QTF,
heart rate-corrected QT interval. *P  0.05 vs. controls; †P  0.05 vs.
baseline.
Fig. 2. Corrected QT (QTC) interval in 43 patients with cirrhosis and controls
at baseline and after 100% oxygen inhalation. *P  0.001 vs. controls.
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There was no significant difference between circulating
norepinephrine level between patients and controls. In the
cirrhotic patients, plasma norepinephrine correlated with
splanchnic hemodynamics such as hepatic blood flow (r 
0.38, P  0.02) and mean arterial blood pressure (r 
0.39, P  0.01) but not with BRS. There was no significant
change in norepinephrine after oxygen inhalation.
There was no significant difference in ET-1 between patients
and controls and no significant change in neither of the groups
after oxygen inhalation. ET-1 correlated to indicators of met-
abolic liver function such as ICG clearance (r  0.37, P 
0.02) and portal hypertension (postsinusoidal resistance, r 
0.36, P  0.03) but not to BRS. However, in patients with
HPS, circulating ET-1 was significantly higher than in those
without (6.9  1.3 vs. 2.9  1.2 fmol/ml, P  0.0001).
DISCUSSION
The main findings of the present study are the following:
1) BRS is significantly reduced in patients with cirrhosis and
that pulmonary dysfunction is prevalent with 10% of the
patients having a HPS. However, we were unable to reveal a
causal relationship between pulmonary dysfunction and the
impaired BRS. 2) BRS was on the other hand associated with
metabolic and hemodynamic characteristics of the liver dis-
ease. 3) After 100% oxygen inhalation BRS remained low in
the cirrhotic patients. 4) The QT interval was prolonged in the
cirrhotic patients and correlated with BRS, but oxygen inhala-
tion had no effect on the adjusted QT interval. 5) Plasma
concentrations of renin, aldosterone, pro-ANP, and BNP were
increased in cirrhosis. After oxygen inhalation, renin and
aldosterone concentrations decreased, whereas pro-ANP and
BNP concentrations increased. No significant relations to the
reduced BRS and vasoactive substances were seen.
It is well documented that patients with cirrhosis exhibit
severe cardiovascular disturbances with impaired regulation of
the systemic blood pressure, CO, and HR (17, 22, 36). This
was confirmed by an increase both in BNP and pro-ANP and
a relation to the change in BNP and BRS in our study. The
entity cirrhotic cardiomyopathy reflects the notion that a latent
cardiac dysfunction plays a role for the development of com-
plications of cirrhosis and portal hypertension and the outcome
in these patients (27, 48). Several studies have revealed an
impaired cardiopulmonary baroreflex function with abnormal
response to pharmacological vasodilatation and changes in
posture (19, 23, 35). BRS is increasingly used as an indicator
of the status of the cardiac autonomic control. Reduced BRS
sensitivity has previously been described in these patients with
relations to severity of the liver disease (3, 32, 37, 46). In
cirrhotic patients, a low BRS indirectly expresses a reduced
vagal tone and significantly contributes to the impaired cardio-
vascular regulation (2, 3, 10). In addition, cirrhotic patients
have a pulmonary dysfunction with arterial hypoxemia and
reduced lung diffusing capacity, since this is seen in more than
80% of the patients (31, 33, 49). The present article was based
on the hypothesis that the reduced BRS could at least partly be
attributed to arterial hypoxemia owing to the pulmonary dys-
function and that normalization of the low PaO2 values would
improve the BRS. This hypothesis lend substrate from the
observation that arterial hypoxemia from a sojourn in high
altitude or exposure to simulated altitudes (low oxygen pres-
sure) reduces BRS in otherwise healthy individuals by 	30%
(43, 44). Results of several studies indicate that the changes in
BRS are less pronounced after acute exposure of hypoxia and
that BRS normalizes after returning to levels with normal
oxygen pressure (12, 40). The mechanisms behind the reduc-
tion in BRS could be changes in cardiac sympathetic activation
and parasympathetic withdrawal (43, 44). In our patients,
hyperoxia had no effect on circulating norepinephrine concen-
trations. However, baseline norepinephrine concentrations
were not significantly increased in the patients, which could be
explained by the relatively low number of Child class C
patients. It has also been observed that patients with chronic
obstructive pulmonary disease exhibit low BRS inversely re-
lated to pulmonary artery pressure (38). In these patients, the
reduced BRS may be caused by a combination of pulmonary
hypertension, hypoxia, and hypercapnia. In our cirrhotic pa-
tients, we were unable to increase the low BRS by inducing
hyperoxia with 100% oxygen inhalation. The impaired BRS in
cirrhosis therefore appears refractory to changes in oxygen-
ation and it is unlikely, therefore, that it is caused by a
pulmonary dysfunction including arterial hypoxemia. The ab-
sence of direct correlations between oxygen saturation, lung
DLCO/VA, and (A-a)PO2 and BRS supports this notion. How-
ever, since we found that a slight but insignificant trend toward
an increase in BRS occurred in the patients after oxygen
inhalation and that only one-third of the patients had significant
hypoxemia, it cannot be ruled out that oxygen inhalation in a
population of patients with more severe pulmonary dysfunction
and a higher frequency of HPS or prolongation of the oxygen
supply would have had a more pronounced effect.
Reduced BRS seems an ominous sign in cirrhosis. Thus
Genovesi et al. (10) recently showed that the reduced BRS in
cirrhosis was significantly related to the degree of portal
hypertension and survival. In our study we were unable to
demonstrate a direct relation between the hepatic venous pres-
sure gradient and BRS. On the other hand we found that the
Table 5. Vasoactive substances in 43 patients with cirrhosis and in 12 controls at baseline and after oxygen inhalation
Cirrhosis Baseline Cirrhosis After O2-Inhalation Controls Baseline Controls After O2-Inhalation
Norepinephrine, ng/ml 0.27 (0.11–0.39) 0.19 (0.08–0.38) 0.32 (0.18–0.42) 0.27 (0.23–0.36)
Renin, pg/ml 30 (10–81)* 28 (9–68)*‡ 8 (6–9) 7 (6–9)
Aldosterone, pmol/l 63 (20–365)* 61 (11–277)*‡ 22 (11–70) 11 (11–50)‡
Angiotensin II, pg/ml 9.7 (5.4–30.0) 11.6 (5.0–21.5) 12.7 (9.8–13.7) 10.2 (7.3–12.8)
Endothelin-1, fmol/ml 1.3 (0.3–3.1) 1.2 (0.4–3.3) 2.1 (0.6–4.5) 1.1 (0.6–1.7)
Pro-ANP, nmol/ml 3.4 (2.6–4.4)* 3.5 (2.7–4.4)*† 2.0 (1.2–2.7) 1.8 (1.1–2.5)
BNP, pg/ml 46 (27–90)* 63 (32–92)*‡ 20 (12–24) 18 (15–29)
Data are given in medians and interquartile ranges. ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide. *P  0.01 vs. controls, †P  0.05 vs.
baseline, ‡P  0.01 vs. baseline.
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low BRS in the cirrhotic patients correlated with HR and AC,
and after oxygen inhalation MAP increased significantly in the
patients and the HR decreased. This indicates that, although the
hemodynamic response was modest, it was possible to affect
other components of the cardiovascular system by increasing
the oxygen supply. Effects of oxygen supply have previously
been reported but the results are inconstant, some showing
beneficial effects while others do not (18, 24). Taken together,
it appears that all the cardiovascular effects of oxygen inhala-
tion in cirrhosis are modest and temporary and that it may not
be possible significantly to revert the hyperdynamic syndrome
by this method.
A prolonged QT interval has been reported in several studies
with relations to splanchnic and systemic hemodynamics and
survival (13, 50, 51). In this study, we confirmed that prolon-
gation of the QT intervals in patients with advanced cirrhosis
correlates with BRS, indicators of liver dysfunction such as the
MELD score, and central systemic hemodynamics such as
CBV and SV. The QT interval also correlated with HR at
baseline. After oxygen inhalation, the QTC and QTF intervals
did not change significantly but the uncorrected QT interval
increased further, possibly owing to the concomitant decrease
in HR and increase in R-R interval. Results of previous studies
have shown that in cirrhosis it is possible partly to normalize
the prolonged QT interval by acute or chronic administration of
beta-blockers (14, 52). However, the prolonged QT interval in
cirrhosis seem refractory for treatment by oxygen supply.
However, the significant associations between the prolonged
QT interval on the one hand and the reduced BRS, low CBV,
SV, and indicators of liver dysfunction on the other underline
that the electromechanical disturbances are an integrated part
of the hepatic and cardiovascular dysfunction in cirrhosis.
The hyperdynamic syndrome with the characteristic hemo-
dynamic changes in cirrhosis is largely pertaining to a prefer-
ential arterial vasodilatation with a reduced SVR (17). Several
vasoconstrictive counterregulatory systems are activated such
as the RAAS, SNS, ANPs, and the endothelin system (28). The
results of this study confirm the activation of several of these
systems. In particular, the RAAS system was suppressible by
oxygen inhalation whereas pro-ANP and BNP increased fur-
ther. Significant correlations between the vasoactive sub-
stances and splanchnic and systemic hemodynamics indicate
an intimate relation between these systems and the abnormal
hemodynamic regulation. However, in this study we found no
significant relations between the low BRS and the measured
vasoactive substances. In experimental models of HPS, the
endothelin system has been implicated in the pathophysiology
(7). Overexpression of the vascular endothelial ETB receptor in
the lungs in animals with experimental HPS may lead to
increased NO release after ET-1 stimulation and pulmonary
vasodilatation (20). Our findings of increased circulating ET-1
concentrations in patients with HPS support this assumption.
However, these pathophysiological mechanisms still need to be
verified in human HPS.
In conclusion, the BRS is reduced in cirrhosis, but it is
unrelated to the degree of pulmonary dysfunction. Oxygen
inhalation failed to normalize the reduced BRS and the pro-
longed QT interval, indicating that pulmonary dysfunction and
arterial hypoxemia per se plays a minor role in the abnormal
cardiovascular regulation in cirrhosis and portal hypertension.
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